Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Jackson on the Toxicity Profile of Lenalidomide Maintenance in Myeloma

February 9th 2017

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses the toxicity profile of lenalidomide maintenance therapy in the treatment of patients with multiple myeloma.

Dr. Usmani on Subcutaneous Delivery of Daratumumab in Myeloma

February 7th 2017

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses administering daratumumab (Darzalex) in patients with relapsed or refractory multiple myeloma.

Dr. Giralt on Future of Transplant in Multiple Myeloma

February 2nd 2017

Sergio Giralt, MD, a professor of Medicine at Memorial Sloan Kettering Cancer Center, discusses the future role of transplantation in patients with multiple myeloma as well as other hematologic malignancies.

CHMP Recommends Approval of Maintenance Lenalidomide in Post-ASCT Myeloma

January 28th 2017

The EMA’s Committee for Medicinal Products for Human Use has recommended approval of lenalidomide as a maintenance therapy following autologous stem cell transplant for patients with newly diagnosed multiple myeloma.

Expert Discusses Key Daratumumab Data Presented at ASH

January 25th 2017

Saad Z. Usmani, MD, discusses the latest developments with daratumumab in the treatment of patients with multiple myeloma, many of which were presented at the recent 2016 ASH Annual Meeting.

Dr. Kumar on the Safety and Efficacy of Venetoclax in Myeloma

January 24th 2017

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses the safety profile and the survival benefits associated with venetoclax in the treatment of patients with multiple myeloma.

Dr. Landgren on Daratumumab Triplet in Relapsed Myeloma

January 19th 2017

C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses the use of the triplet of daratumumab, bortezomib, and dexamethasone in the treatment of patients with relapsed myeloma.

Expert Touts Value of Lenalidomide Maintenance in Myeloma

January 19th 2017

Lenalidomide as a maintenance treatment for patients with newly diagnosed symptomatic multiple myeloma demonstrated encouraging phase III findings in the Myeloma X1 trial, which were presented at the 2016 ASH Annual Meeting.

Dr. Jackson on Benefits of Maintenance Therapy for Myeloma

January 18th 2017

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses the benefits of maintenance therapy for patients with multiple myeloma.

Immunotherapy for Myeloma & Final Thoughts on Myeloma Research at ASH 2016

January 17th 2017

Emerging Therapies for Myeloma

January 17th 2017

Choosing Triplet Therapy at Myeloma Relapse

January 17th 2017

Relapsed/Refractory Myeloma: Daratumumab-Containing Triplets

January 17th 2017

Elderly Patients With Myeloma

January 17th 2017

Consolidation/Maintenance Therapy in Myeloma

January 17th 2017

Transplant in Multiple Myeloma

January 17th 2017

Which Proteasome Inhibitor for Upfront Treatment of Myeloma?

January 17th 2017

New Data for Newly Diagnosed Myeloma

January 17th 2017

Treating High-Risk Asymptomatic Myeloma

January 17th 2017

Classifying Indolent Versus Active Myeloma

January 17th 2017